S2 Genomics, Inc.

[On Demand]

S2 Genomics, Inc. has developed the Singulator™ 100 System to automate and standardize the production of single cells or nuclei from solid tissues for single cell biology. The system integrates an instrument, single-use cartridges, and reagents to quickly and gently dissociate solid tissues. This solves the main pain point for customers who process solid tissues for single cell genomics and biology . A wide range of human and other tissues processed on the Singulator have been sequenced by scRNA-Seq, snRNA-Seq, and ATAC-Seq by our customers. The Company released the commercial Singulator system in December 2020 and has placed systems in leading institutions worldwide.

S2 Genomics, Inc. is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Singulator 100 System to dissociate solid tissue to single cells and nuclei
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Applications of world class solid tissue dissociation
S2 Genomics, Inc.